MD, PhD  

Vladislav Khairutdinov


Presentations

The adalimumab biosimilar BCD-057 vs. innovator adalimumab in patients with moderate-to-severe plaque psoriasis: 55-week results from Phase 3/CALYPSO study 09 October 2019 00:00 - 00:00

Abstracts

The adalimumab biosimilar BCD-057 vs. innovator adalimumab in patients with moderate-to-severe plaque psoriasis: 55-week results from Phase 3/CALYPSO study Psoriasis More